Ruxolitinib formulation for reduction of itch in atopic dermatitis

USPTO granted Patent US12589096B2 to Incyte Corporation for a ruxolitinib cream formulation effective against atopic dermatitis itch. The patent covers topical compositions containing 0.75% or 1.5% ruxolitinib applied twice daily. Filing date was July 21, 2025, with Application No. 19274703 and 20 claims total.

This is a routine patent grant, not a regulatory action. No compliance deadlines, penalties, or required actions apply to third parties. Pharmaceutical companies and researchers should note this patent when developing competing itch treatments for atopic dermatitis to avoid infringement on the granted claims.